Robert Doody, who led invesotor relations for ViroPharma through its $4.2B acquisition by Shire last year, has landed at Idera Pharmaceuticals as VP of IR and corporate communications for the Waltham, Mass.-based biopharma developer.

Doody is reunited with former ViroPharma CEO Vincent Milano, who now helms Idera. He spent more than seven years at ViroPharma in Exton, Pa., and served on its integration time with Shire through May of this year.

Doody was previously an A/S at Dorland Sweeny Jones.

Idera is a publicly traded, clinical-stage biopharmaceutical developer. Its lead drug candidate, IMO-8400, is aimed at autoimmune disease.